Plasmablastic Lymphoma

general

An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.

38

Centers

38

Active Trials

$5M

Cancer Funding

Specific Cancer Types(1)

NameCenters
Recurrent Plasmablastic Lymphoma4

Top Centers for Plasmablastic Lymphoma(38)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
72.3
2
NCI Comprehensive
High-Volume Research Center
71.3
3
NCI Comprehensive
High-Volume Research Center
70.4
4
NCI Comprehensive
Active Research Program
67.6
5
NCI Comprehensive
Active Research Program
67.6
6
NCI Comprehensive
Active Research Program
67.6
7
NCI Clinical
Active Research Program
67.6
8
NCI Comprehensive
Active Research Program
67.6
9
Active Research Program
67.6
10
Active Research Program
67.6
11
NCI Comprehensive
Active Research Program
53.4
12
NCI Comprehensive
Active Research Program
53.4
13
NCI Comprehensive
Active Research Program
53.4
14
NCI Comprehensive
Active Research Program
53.4
15
NCI Comprehensive
Active Research Program
53.4
16
NCI Comprehensive
Active Research Program
53.4
1753.4
18
NCI Comprehensive
Active Research Program
53.4
19
NCI Comprehensive
Active Research Program
53.4
20
Active Research Program
53.4
21
NCI Comprehensive
Active Research Program
53.4
22
NCI Comprehensive
Active Research Program
53.4
23
Active Research Program
53.4
24
Active Research Program
53.4
25
Active Research Program
53.4
26
NCI Comprehensive
35.6
27
NCI Comprehensive
35.6
2835.6
29
NCI Comprehensive
35.6
30
NCI Comprehensive
35.6
31
NCI Comprehensive
35.6
3235.6
33
NCI Comprehensive
35.6
3435.6
35
NCI Comprehensive
35.6
3635.6
37
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
35.6
3835.6

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →